Open-label, Phase I Dose-escalation Clinical Study of the Safety, Tolerability and Pharmacokinetics of Single Subcutaneus Dose of BCD-085, Monoclonal Antibody Against IL-17, in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Netakimab (Primary)
- Indications Autoimmune disorders
- Focus First in man; Pharmacokinetics
- Sponsors Biocad
- 11 Jun 2016 Results presented at the 17th Annual Congress of the European League Against Rheumatism
- 12 Jan 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Mar 2015 New trial record